Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Regeneron ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

For more information on Regeneron’s clinical trials in blood cancer, visit the clinical trials website, or contact via [email protected] or 844-734-6643. About Regeneron in Hematology ...

TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ...

NEW YORK - The U.S. Food and Drug Administration has granted accelerated approval to Regeneron Pharmaceuticals’ (NASDAQ:REGN) Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or ...

Regeneron is committed to working closely with the third-party fill/finish manufacturer and the FDA to bring linvoseltamab to appropriate patients with R/R MM as quickly as possible, which is ...

Aktien»Nachrichten»REGENERON PHARMACEUTICALS AKTIE»Regeneron Pharmaceuticals, Inc.: Lynozyfic (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory ...

“Onco360 is grateful for the opportunity to partner with the Regeneron team and become a specialty pharmacy provider for Lynozyfic,” said Benito Fernandez, Chief Commercial Officer.“We are proud to ...

Regeneron, currently trading at an attractive P/E ratio of 12.91 and generating annual revenue of $14.09 billion, appears well-positioned to capture this market opportunity.